Romainville, France, October the 2nd, 2006
Press Release
Cellectis Appoints Marc Le Bozec As Chief Financial Officer.
Romainville, France - October the 2nd, 2006 - Cellectis announced today that it has appointed Marc Le Bozec as its Chief Financial Officer effective October 2, 2006.
Marc Le Bozec (37) was Chief Operating Officer of Alfact Innovation (France). He has more than 10 years experience in the biotech sector as consultant (Arthur D. Little, Paris office) and as founder and Chairman & CEO of BioProtein Technologies (France), a biotech company dedicated to the production of recombinant proteins in the milk of transgenic animals. He is graduated from HEC School of Management, Paris.
"I am excited to join Cellectis at this very important phase of the Company" commented Mr. Le Bozec. "Cellectis has succeeded building a unique position in genome reprogramming, which represents the next frontier of the worldwide biotech industry. I believe that I can make a significant contribution to the further growth of the Company through my complementary background in consolidating fast-growing biotech companies."
Dr. André Choulika, co-founder and CEO commented: "Cellectis is very pleased to welcome Marc Le Bozec into our management team. I am firmly convinced that his experience in the biotechnology field, in particular in business and finance, will be of great value to the leadership and the success of Cellectis."
Cellectis SA (www.cellectis.com) was founded in 2000, as a spin-off from the Institut Pasteur. Today, Cellectis is the world leader in applying the technology of Meganuclease Recombination Systems to in vivo genome engineering and genome surgery. The company is focused on the research and development of custom-made Meganucleases for in vivo DNA interventions and also provides new tools for rational reverse genetics and targeted recombination. Cellectis develops Meganucleases that can induce unique site-directed double-strand breaks in a living cell, and can be used for biotechnological and therapeutical applications. The company is focusing on bringing "genome surgery" to clinic as a genuine new molecular medicine approach.
As of today Cellectis has entered into more than 40 deals on its Genome Engineering technologies.
Copyright © Cellectis 2006. All rights reserved.
|
